Key result
Paroxysmal sympathetic hyperactivity requires early recognition and prompt management with opioids, alpha-2 agonists, and beta-blockers.
Why the study?
Paroxysmal sympathetic hyperactivity is a frequent clinical syndrome in severe brain injury patients in the neuroICU with unclear pathophysiology requiring early recognition and management.
Early recognition and prompt management of paroxysmal sympathetic hyperactivity is mandatory in patients with severe brain injury.
Paroxysmal sympathetic hyperactivity (PSH) is a well-known clinical syndrome, which is frequently encountered in treating patients with severe brain injury including traumatic brain injury, hypoxic ischemic injury and severe stroke in the neuroICU.PSH is characterized by episodic hypertension, tachycardia, tachypnea, excessive diaphoresis, fever, and pathologic posturing.Although its pathophysiology is still not clearly understood, its early recognition and prompt management is mandatory in patients with brain injury.Herein, we briefly reviewed the diagnosis, prognosis and treatment of PSH.
No takes yet. Share an insight, caveat, or question.
Sang‐Bae Ko (2015) conducted a review in Paroxysmal Sympathetic Hyperactivity. Paroxysmal sympathetic hyperactivity is a severe syndrome in brain injury patients that requires early recognition and prompt management with medications such as opioids, alpha-2 agonists, and beta-blockers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: